Rhonda Legendre
Family · Rosepine, LANPI 1871131631
Payments from drug & device makers
Across 135 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$506
- Boehringer Ingelheim$431
- Novo Nordisk$264
- AstraZeneca$239
- Lilly USA, LLC$125
- Astellas Pharma US Inc$111
- plus $665 from 21 others
What the payments were for
- Food & beverage$2,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $506 |
| Boehringer Ingelheim | 25 | $431 |
| Novo Nordisk | 13 | $264 |
| AstraZeneca | 14 | $239 |
| Lilly USA, LLC | 7 | $125 |
| Astellas Pharma US Inc | 6 | $111 |
| Sunovion Pharmaceuticals Inc. | 6 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Novartis | 3 | $49 |
| Abbott | 3 | $47 |
| GSK | 2 | $43 |
| Antares Pharma, Inc. | 2 | $39 |
| Amgen | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Bayer | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$2,341 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $40,115 |
| OzempicSemaglutide | 30 | $28,661 |
| JardianceEmpagliflozin | 35 | $27,087 |
| MyrbetriqMirabegron | 24 | $12,656 |
| RybelsusSemaglutide | 14 | $9,716 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,903 |
| Gabapentin | 99 | $1,585 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,199 |
| Atorvastatin Calcium | 130 | $804 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $779 |
| Pantoprazole Sodium | 60 | $680 |
| Sucralfate | 11 | $466 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $407 |
| Ezetimibe | 22 | $406 |
| Lisinopril | 125 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $43 | $40,11549 claims |
| Novo NordiskOzempic, Rybelsus | $264 | $38,37744 claims |
| Boehringer IngelheimJardiance | $431 | $27,08735 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $12,65624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Rosepine
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.